Papillary thyroid cancer (PTC) offers excellent prognosis, however relapse risk or persistent
disease is related to~ 30%. Currently, attention is paid to the possibility of patient group …

Abstract Background The BRAF V600E mutation has been adopted as a prognostic factor in
papillary thyroid carcinoma (PTC). However, it remains unclear whether routine BRAF …

Introduction The risk of over-treatment in low-advanced PTC stages has prompted clinicians
to search for new reliable prognostic factors. The presence of BRAF mutation, the most …

Summary Background The activating BRAFV600E mutation is the most common genetic
alteration reported in papillary thyroid carcinoma (PTC). While some reports suggest the …

Papillary carcinoma is the most prevalent malignancy of thyroid gland, and its incidence has
been recently increased. The BRAF V600E mutation is the most frequent genetic alteration …

BACKGROUND. Numerous studies have investigated the clinical significance of BRAF
mutation in papillary thyroid carcinoma (PTC). However, there have been conflicting data on …

Introduction: There have been contradictory data on whether or not BRAF V600E mutation
should be regard as a poor prognosis predictor of papillary thyroid carcinoma (PTC). To …

The aim of the present study was to investigate the prevalence of the BRAF V600E mutation
in papillary thyroid carcinoma (PTC) and to determine the correlation between this mutation …

BACKGROUND: The effects of the BRAFV600E mutation on prognostic factors and poor
clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The …

Abstract The mutation BRAF V600E is thought to be a putative prognostic marker of the
aggressiveness of several cancers among which is also papillary thyroid cancer. Our study …